Symbols / ALLR $1.16 +2.65% Allarity Therapeutics, Inc.
ALLR Chart
About
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 18.65M |
| Enterprise Value | 5.06M | Income | -11.23M | Sales | 320.00K |
| Book/sh | 0.61 | Cash/sh | 0.93 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | 0.11 | Forward P/E | -1.20 | PEG | — |
| P/S | 58.29 | P/B | 1.90 | P/C | — |
| EV/EBITDA | -0.40 | EV/Sales | 15.82 | Quick Ratio | 1.84 |
| Current Ratio | 2.13 | Debt/Eq | 14.24 | LT Debt/Eq | — |
| EPS (ttm) | -0.78 | EPS next Y | -0.97 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-30 17:00 | ROA | -38.52% |
| ROE | -103.80% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -9.12% | Profit Margin | 0.00% | Shs Outstand | 16.08M |
| Shs Float | 15.79M | Short Float | 1.80% | Short Ratio | 1.43 |
| Short Interest | — | 52W High | 2.35 | 52W Low | 0.61 |
| Beta | — | Avg Volume | 167.89K | Volume | 55.11K |
| Target Price | $9.50 | Recom | None | Prev Close | $1.13 |
| Price | $1.16 | Change | 2.65% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-09 | main | Ascendiant Capital | Buy → Buy | $10 |
| 2025-09-26 | main | Ascendiant Capital | Buy → Buy | $9 |
| 2025-07-28 | init | Ascendiant Capital | — → Buy | $9 |
- Allarity Therapeutics, Inc. (ALLR) stock price, news, quote and history - Yahoo Finance UK hu, 02 Apr 2026 20
- Cancer drug gets FDA Fast Track as Allarity says cash lasts to 2028 - Stock Titan ue, 31 Mar 2026 12
- ALLR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI Wed, 01 Apr 2026 06
- Allarity Therapeutics, Inc. (ALLR) Reports FY2025 Earnings - AlphaStreet ue, 31 Mar 2026 13
- Allarity Therapeutics (NASDAQ: ALLR) cuts 2025 loss to $11.2M and posts first revenue - Stock Titan Wed, 01 Apr 2026 12
- Should I buy Allarity Therapeutics, Inc. (ALLR) - zacks.com Fri, 29 Aug 2025 07
- Allarity Therapeutics stock soars after FDA Fast Track designation - Investing.com ue, 26 Aug 2025 07
- Allarity Therapeutics Signs Common Stock Purchase Agreement With Tumim Stone Capital - tradingview.com hu, 29 Jan 2026 08
- Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today? - TipRanks ue, 26 Aug 2025 07
- Why Did Allarity Therapeutics Stock Double In Value Today? - Stocktwits ue, 26 Aug 2025 17
- Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - Sahm ue, 31 Mar 2026 07
- Allarity Therapeutics Delays 10-Q Filing - The Globe and Mail Fri, 15 Aug 2025 07
- Allaritys Earnings Stasis Masks Three-Year Loss Streak - bitget.com Mon, 30 Mar 2026 14
- Ovarian cancer drug keeping patients 30+ months gets $20M boost - Stock Titan Fri, 06 Mar 2026 08
- Allarity Therapeutics Secures $20 Million Structured Note Financing - TipRanks Fri, 06 Mar 2026 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.32
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.32
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
12.93
-26.30%
|
17.54
+2.39%
|
17.13
+1.40%
|
16.89
|
| Research And Development |
|
6.60
+8.28%
|
6.10
-14.18%
|
7.10
+2.50%
|
6.93
|
| Selling General And Administration |
|
6.32
-44.73%
|
11.44
+14.12%
|
10.03
+0.64%
|
9.96
|
| General And Administrative Expense |
|
6.32
-44.73%
|
11.44
+14.12%
|
10.03
+0.64%
|
9.96
|
| Other Gand A |
|
6.32
-44.73%
|
11.44
+14.12%
|
10.03
+0.64%
|
9.96
|
| Total Expenses |
|
12.93
-26.30%
|
17.54
+2.39%
|
17.13
+1.40%
|
16.89
|
| Operating Income |
|
-12.61
+28.13%
|
-17.54
-2.39%
|
-17.13
-1.40%
|
-16.89
|
| Total Operating Income As Reported |
|
-12.61
+53.73%
|
-27.24
-59.03%
|
-17.13
+50.30%
|
-34.46
|
| EBITDA |
|
-11.05
+54.42%
|
-24.23
-114.78%
|
-11.28
+34.77%
|
-17.30
|
| Normalized EBITDA |
|
-11.80
+30.55%
|
-17.00
+3.77%
|
-17.66
-5.11%
|
-16.80
|
| Reconciled Depreciation |
|
-0.01
-244.44%
|
0.01
-75.68%
|
0.04
-38.33%
|
0.06
|
| EBIT |
|
-11.05
+54.44%
|
-24.24
-114.16%
|
-11.32
+34.78%
|
-17.36
|
| Total Unusual Items |
|
0.76
+110.47%
|
-7.24
-213.48%
|
6.38
+1391.09%
|
-0.49
|
| Total Unusual Items Excluding Goodwill |
|
0.76
+110.47%
|
-7.24
-213.48%
|
6.38
+1391.09%
|
-0.49
|
| Special Income Charges |
|
0.00
+100.00%
|
-9.70
|
0.00
+100.00%
|
-16.59
|
| Other Special Charges |
|
—
|
—
|
—
|
0.80
|
| Impairment Of Capital Assets |
|
0.00
-100.00%
|
9.70
|
0.00
-100.00%
|
17.57
|
| Net Income |
|
-11.23
+54.19%
|
-24.52
-105.99%
|
-11.90
+25.89%
|
-16.06
|
| Pretax Income |
|
-11.23
+54.89%
|
-24.90
-110.66%
|
-11.82
+32.77%
|
-17.58
|
| Net Non Operating Interest Income Expense |
|
0.62
+613.33%
|
-0.12
+74.79%
|
-0.48
-146.63%
|
-0.19
|
| Interest Expense Non Operating |
|
0.18
-71.67%
|
0.65
+31.12%
|
0.50
+123.32%
|
0.22
|
| Net Interest Income |
|
0.62
+613.33%
|
-0.12
+74.79%
|
-0.48
-146.63%
|
-0.19
|
| Interest Expense |
|
0.18
-71.67%
|
0.65
+31.12%
|
0.50
+123.32%
|
0.22
|
| Interest Income Non Operating |
|
0.80
+50.28%
|
0.53
+2322.73%
|
0.02
-26.67%
|
0.03
|
| Interest Income |
|
0.80
+50.28%
|
0.53
+2322.73%
|
0.02
-26.67%
|
0.03
|
| Other Income Expense |
|
0.76
+110.47%
|
-7.24
-225.07%
|
5.79
+1271.46%
|
-0.49
|
| Other Non Operating Income Expenses |
|
—
|
—
|
-0.59
|
—
|
| Gain On Sale Of Security |
|
0.76
-69.25%
|
2.46
-61.35%
|
6.38
-60.38%
|
16.10
|
| Tax Provision |
|
0.00
+100.00%
|
-0.38
-559.04%
|
0.08
+105.46%
|
-1.52
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
-92.71%
|
0.00
+142.71%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.11
-108.27%
|
1.34
+3233.59%
|
-0.04
|
| Net Income Including Noncontrolling Interests |
|
-11.23
+54.19%
|
-24.52
-105.99%
|
-11.90
+25.89%
|
-16.06
|
| Net Income From Continuing Operation Net Minority Interest |
|
-11.23
+54.19%
|
-24.52
-105.99%
|
-11.90
+25.89%
|
-16.06
|
| Net Income From Continuing And Discontinued Operation |
|
-11.23
+54.19%
|
-24.52
-105.99%
|
-11.90
+25.89%
|
-16.06
|
| Net Income Continuous Operations |
|
-11.23
+54.19%
|
-24.52
-105.99%
|
-11.90
+25.89%
|
-16.06
|
| Minority Interests |
|
—
|
—
|
—
|
—
|
| Normalized Income |
|
-11.99
+31.05%
|
-17.39
-2.65%
|
-16.94
-8.54%
|
-15.61
|
| Net Income Common Stockholders |
|
-11.23
+55.35%
|
-25.15
-23.21%
|
-20.42
+3.02%
|
-21.05
|
| Diluted EPS |
|
—
|
-15.65
+99.74%
|
-6,031.31
+81.03%
|
-31,799.09
|
| Basic EPS |
|
—
|
-15.65
+99.74%
|
-6,031.31
+81.03%
|
-31,799.09
|
| Basic Average Shares |
|
—
|
7.30
+215639.94%
|
0.00
+411.33%
|
0.00
|
| Diluted Average Shares |
|
—
|
7.30
+215639.94%
|
0.00
+411.33%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-11.23
+55.35%
|
-25.15
-23.21%
|
-20.42
+3.02%
|
-21.05
|
| Gain On Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
1.78
|
| Preferred Stock Dividends |
|
—
|
0.64
-92.50%
|
8.52
+70.54%
|
4.99
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets |
|
18.26
+53.92%
|
11.86
|
| Current Assets |
|
17.93
+809.59%
|
1.97
|
| Cash Cash Equivalents And Short Term Investments |
|
14.69
+8747.59%
|
0.17
|
| Cash And Cash Equivalents |
|
14.69
+8747.59%
|
0.17
|
| Cash Financial |
|
14.69
+8747.59%
|
0.17
|
| Other Short Term Investments |
|
—
|
—
|
| Receivables |
|
0.90
-5.39%
|
0.95
|
| Accounts Receivable |
|
0.00
|
0.00
|
| Taxes Receivable |
|
0.90
-5.39%
|
0.95
|
| Prepaid Assets |
|
2.35
+173.11%
|
0.86
|
| Current Deferred Assets |
|
—
|
0.00
|
| Total Non Current Assets |
|
0.33
-96.66%
|
9.89
|
| Net PPE |
|
0.33
+1550.00%
|
0.02
|
| Gross PPE |
|
0.33
+1550.00%
|
0.02
|
| Accumulated Depreciation |
|
—
|
—
|
| Other Properties |
|
0.33
+1550.00%
|
0.02
|
| Goodwill And Other Intangible Assets |
|
—
|
9.87
|
| Other Intangible Assets |
|
—
|
9.87
|
| Investments And Advances |
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
8.43
-42.31%
|
14.61
|
| Current Liabilities |
|
8.43
-40.50%
|
14.17
|
| Payables And Accrued Expenses |
|
7.03
-28.15%
|
9.78
|
| Payables |
|
4.36
-48.52%
|
8.47
|
| Accounts Payable |
|
4.28
-49.12%
|
8.42
|
| Current Accrued Expenses |
|
2.67
+103.74%
|
1.31
|
| Total Tax Payable |
|
0.08
+37.29%
|
0.06
|
| Income Tax Payable |
|
0.08
+37.29%
|
0.06
|
| Current Debt And Capital Lease Obligation |
|
1.40
+7.69%
|
1.30
|
| Current Debt |
|
1.40
+7.69%
|
1.30
|
| Other Current Borrowings |
|
1.40
+7.69%
|
1.30
|
| Current Capital Lease Obligation |
|
—
|
0.00
|
| Other Current Liabilities |
|
—
|
3.08
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
-100.00%
|
0.45
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
| Long Term Debt |
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
| Non Current Deferred Liabilities |
|
—
|
0.45
|
| Non Current Deferred Taxes Liabilities |
|
—
|
0.45
|
| Preferred Securities Outside Stock Equity |
|
—
|
0.00
|
| Stockholders Equity |
|
9.83
+457.25%
|
-2.75
|
| Common Stock Equity |
|
9.83
+318.74%
|
-4.49
|
| Capital Stock |
|
0.00
-99.83%
|
1.74
|
| Common Stock |
|
0.00
|
0.00
|
| Preferred Stock |
|
—
|
1.74
|
| Share Issued |
|
18.66
+190073.92%
|
0.01
|
| Ordinary Shares Number |
|
16.06
+163565.27%
|
0.01
|
| Treasury Shares Number |
|
2.60
|
0.00
|
| Additional Paid In Capital |
|
144.23
+59.60%
|
90.37
|
| Retained Earnings |
|
-130.20
-37.85%
|
-94.45
|
| Gains Losses Not Affecting Retained Earnings |
|
-1.02
-148.42%
|
-0.41
|
| Treasury Stock |
|
3.19
|
—
|
| Other Equity Adjustments |
|
-1.02
-148.42%
|
-0.41
|
| Total Equity Gross Minority Interest |
|
9.83
+457.25%
|
-2.75
|
| Total Capitalization |
|
9.83
+457.25%
|
-2.75
|
| Working Capital |
|
9.50
+177.88%
|
-12.20
|
| Invested Capital |
|
11.23
+451.64%
|
-3.19
|
| Total Debt |
|
1.40
+7.69%
|
1.30
|
| Net Debt |
|
—
|
1.13
|
| Capital Lease Obligations |
|
—
|
0.00
|
| Net Tangible Assets |
|
9.83
+177.86%
|
-12.62
|
| Tangible Book Value |
|
9.83
+168.42%
|
-14.36
|
| Available For Sale Securities |
|
—
|
—
|
| Current Notes Payable |
|
—
|
0.00
|
| Derivative Product Liabilities |
|
—
|
—
|
| Interest Payable |
|
0.46
+356.44%
|
0.10
|
| Investmentin Financial Assets |
|
—
|
—
|
| Line Of Credit |
|
—
|
—
|
| Preferred Stock Equity |
|
—
|
1.74
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-14.82
+14.59%
|
-17.35
-36.15%
|
-12.74
+24.21%
|
-16.82
|
| Cash Flow From Continuing Operating Activities |
|
-14.82
+14.59%
|
-17.35
-36.15%
|
-12.74
+24.21%
|
-16.82
|
| Net Income From Continuing Operations |
|
-11.23
+54.19%
|
-24.52
-105.99%
|
-11.90
+25.89%
|
-16.06
|
| Depreciation Amortization Depletion |
|
-0.01
-244.44%
|
0.01
-75.68%
|
0.04
-38.33%
|
0.06
|
| Depreciation And Amortization |
|
-0.01
-244.44%
|
0.01
-75.68%
|
0.04
-38.33%
|
0.06
|
| Other Non Cash Items |
|
0.39
-31.98%
|
0.57
-64.04%
|
1.57
+1040.58%
|
0.14
|
| Stock Based Compensation |
|
0.48
+578.87%
|
0.07
+200.00%
|
-0.07
-104.05%
|
1.75
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
9.70
|
0.00
-100.00%
|
17.57
|
| Deferred Tax |
|
0.00
+100.00%
|
-0.45
-559.79%
|
0.10
+106.02%
|
-1.61
|
| Deferred Income Tax |
|
0.00
+100.00%
|
-0.45
-559.79%
|
0.10
+106.02%
|
-1.61
|
| Operating Gains Losses |
|
1.24
+144.13%
|
-2.80
+51.95%
|
-5.83
+68.20%
|
-18.34
|
| Gain Loss On Investment Securities |
|
-0.00
+99.96%
|
-2.68
+52.65%
|
-5.65
+66.76%
|
-17.01
|
| Net Foreign Currency Exchange Gain Loss |
|
1.24
+1082.54%
|
-0.13
+29.61%
|
-0.18
-139.78%
|
0.45
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
0.00
+100.00%
|
-1.78
|
| Change In Working Capital |
|
-5.68
-9115.87%
|
0.06
-98.12%
|
3.35
+1121.95%
|
-0.33
|
| Change In Receivables |
|
-0.10
-313.33%
|
0.04
+273.08%
|
-0.03
|
0.00
|
| Changes In Account Receivables |
|
—
|
—
|
—
|
—
|
| Change In Prepaid Assets |
|
-1.60
-685.04%
|
0.27
+244.21%
|
-0.19
+69.26%
|
-0.62
|
| Change In Payables And Accrued Expense |
|
-3.83
-587.79%
|
-0.56
-125.02%
|
2.23
+51.84%
|
1.47
|
| Change In Accrued Expense |
|
-2.70
-176.33%
|
3.54
+8123.26%
|
0.04
+100.91%
|
-4.72
|
| Change In Payable |
|
-1.13
+72.34%
|
-4.09
-287.49%
|
2.18
-64.72%
|
6.19
|
| Change In Account Payable |
|
-1.14
+72.27%
|
-4.11
-289.75%
|
2.17
-65.12%
|
6.21
|
| Change In Other Working Capital |
|
—
|
0.21
|
—
|
—
|
| Change In Other Current Assets |
|
-0.15
-259.57%
|
0.09
-93.04%
|
1.35
+225.35%
|
-1.08
|
| Change In Other Current Liabilities |
|
—
|
0.00
+100.00%
|
-0.01
+91.92%
|
-0.10
|
| Investing Cash Flow |
|
-0.01
+97.32%
|
-0.30
|
0.00
-100.00%
|
0.79
|
| Cash Flow From Continuing Investing Activities |
|
-0.01
+97.32%
|
-0.30
|
0.00
-100.00%
|
0.79
|
| Net PPE Purchase And Sale |
|
-0.01
+97.32%
|
-0.30
|
0.00
+100.00%
|
-0.02
|
| Purchase Of PPE |
|
-0.01
+97.32%
|
-0.30
|
0.00
+100.00%
|
-0.02
|
| Capital Expenditure |
|
-0.01
+97.32%
|
-0.30
|
—
|
-0.02
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
-100.00%
|
0.81
|
| Financing Cash Flow |
|
10.65
-71.06%
|
36.79
+234.62%
|
10.99
+938.67%
|
-1.31
|
| Cash Flow From Continuing Financing Activities |
|
10.65
-71.06%
|
36.79
+234.62%
|
10.99
+938.67%
|
-1.31
|
| Net Issuance Payments Of Debt |
|
0.00
|
0.00
+100.00%
|
-2.65
-364.90%
|
1.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
1.34
+27.62%
|
1.05
+5.00%
|
1.00
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-1.34
+63.77%
|
-3.70
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
1.34
+27.62%
|
1.05
+5.00%
|
1.00
|
| Long Term Debt Payments |
|
0.00
+100.00%
|
-1.34
+63.77%
|
-3.70
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
|
0.00
+100.00%
|
-2.65
-364.90%
|
1.00
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
10.65
-71.49%
|
37.35
+121.09%
|
16.89
|
0.00
|
| Common Stock Payments |
|
-3.19
|
0.00
|
—
|
—
|
| Repurchase Of Capital Stock |
|
-3.19
+8.86%
|
-3.50
+47.40%
|
-6.65
-340.37%
|
-1.51
|
| Proceeds From Stock Option Exercised |
|
—
|
0.00
-100.00%
|
2.24
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
-0.80
|
| Changes In Cash |
|
-4.18
-121.83%
|
19.14
+1193.83%
|
-1.75
+89.91%
|
-17.34
|
| Effect Of Exchange Rate Changes |
|
-0.67
-396.44%
|
0.23
+299.12%
|
-0.11
+40.21%
|
-0.19
|
| Beginning Cash Position |
|
19.53
+11666.87%
|
0.17
-91.82%
|
2.03
-89.62%
|
19.55
|
| End Cash Position |
|
14.69
-24.81%
|
19.53
+11666.87%
|
0.17
-91.82%
|
2.03
|
| Free Cash Flow |
|
-14.83
+15.99%
|
-17.65
-38.49%
|
-12.74
+24.29%
|
-16.84
|
| Interest Paid Supplemental Data |
|
—
|
—
|
0.03
-60.00%
|
0.09
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.01
-50.00%
|
0.01
|
| Change In Income Tax Payable |
|
0.01
-53.33%
|
0.01
-16.67%
|
0.02
+194.74%
|
-0.02
|
| Change In Tax Payable |
|
0.01
-53.33%
|
0.01
-16.67%
|
0.02
+194.74%
|
-0.02
|
| Common Stock Issuance |
|
13.84
-62.95%
|
37.35
+121.09%
|
16.89
|
0.00
|
| Issuance Of Capital Stock |
|
13.84
-65.66%
|
40.29
+123.16%
|
18.05
|
0.00
|
| Net Preferred Stock Issuance |
|
0.00
+100.00%
|
-0.56
+89.77%
|
-5.49
-263.60%
|
-1.51
|
| Preferred Stock Issuance |
|
0.00
-100.00%
|
2.94
+153.28%
|
1.16
|
0.00
|
| Preferred Stock Payments |
|
0.00
+100.00%
|
-3.50
+47.40%
|
-6.65
-340.37%
|
-1.51
|
| Sale Of Intangibles |
|
—
|
—
|
0.00
-100.00%
|
0.81
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-01 View
- 10-K2026-03-30 View
- 8-K2026-03-09 View
- 8-K2026-03-06 View
- 8-K2026-02-19 View
- 8-K2026-02-04 View
- 8-K2026-01-29 View
- 42026-01-16 View
- 8-K2025-12-23 View
- 8-K2025-12-08 View
- 10-Q2025-11-14 View
- 42025-10-02 View
- 8-K2025-09-24 View
- 8-K2025-09-22 View
- 8-K2025-09-22 View
- 8-K2025-08-27 View
- 10-Q2025-08-15 View
- 8-K2025-07-16 View
- 8-K2025-07-07 View
- 8-K2025-07-01 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|